title: Jaundice and hepatocellular damage associated with nevirapine therapy.
abstract: OBJECTIVE
  Nevirapine is a nonnucleoside reverse transcription inhibitor that is used as part of highly active antiretroviral therapeutic combinations. Nevirapine has been associated with a skin rash in 32 to 48% of patients. Recent reports indicate that hepatic toxicity also occurs.
  
  
  METHODS
  We describe four instances of reversible hepatocellular damage associated with the use of nevirapine in patients with HIV infection. Two of the four patients were also coinfected with the hepatitis C virus.
  
  
  RESULTS
  Evidence of malaise, skin rash, and icteric hepatitis with pruritus occurred 4-6 wk after the beginning of nevirapine therapy. No evidence of metabolic acidosis was present in any of our patients. In all cases, liver test results declined to normal or near normal levels, and pruritus disappeared 4-6 wk after discontinuation of the medication. No patient was rechallenged with the drug.
  
  
  CONCLUSIONS
  Nevirapine can be associated with icteric hepatitis, which appears to be reversible after withdrawal of the drug.
authors.affiliation: Division of Infectious Diseases, Keck School of Medicine, Los Angeles, California, USA.
authors.forename: M
authors.initials: M
authors.lastname: Prakash
authors.forename: V
authors.initials: V
authors.lastname: Poreddy
authors.forename: L
authors.initials: L
authors.lastname: Tiyyagura
authors.forename: M
authors.initials: M
authors.lastname: Bonacini
mesh_terms: D000328:Adult; D056486:Chemical and Drug Induced Liver Injury; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D007565:Jaundice / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000009:adverse effects* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
chemical_list: D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine